IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity
Zhao, Xiao-su1,2; Yan, Chen-hua1,2; Liu, Dai-hong1,2; Xu, Lan-ping1,2; Liu, Yan-rong1,2; Liu, Kai-yan1,2; Qin, Ya-zhen1,2; Wang, Yu1,2; Huang, Xiao-jun1,2
关键词Allogeneic hematopoietic stem cell transplantation Wilms&prime tumor gene 1 Relapse Minimal residual diseases Flow cytometry
刊名ANNALS OF HEMATOLOGY
2013-08-01
DOI10.1007/s00277-013-1733-1
92期:8页:1111-1119
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]MINIMAL RESIDUAL DISEASE ; ACUTE MYELOID-LEUKEMIA ; STEM-CELL TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; POLYMERASE-CHAIN-REACTION ; TUMOR GENE WT1 ; ACUTE LYMPHOBLASTIC-LEUKEMIA ; PROGNOSTIC-FACTORS ; CANCER PROGRAM ; BONE-MARROW
英文摘要

Either WT1 or leukemia-associated aberrant immune phenotypes (LAIPs) was one of the minimal residual disease (MRD) parameters used to predict leukemia relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We first evaluated the clinical value of various positive MRD standards for accurately indicating relapse based on WT1 and FCM data in adult patients with acute leukemia (AL). In total, 824 AL patients treated with allo-HSCT were enrolled in this study. We compared the sensitivity and specificity of diverse, multiple-criteria MRD prognostic standards based on WT1 and FCM assays. Higher sensitivity was achieved without a loss of specificity when MRDco+, which was defined as two consecutive WT1(0.6)+ or FCM+ or both WT1(0.6)+ and FCM+ in the same sample within a year posttransplantation, was used as the positive MRD standard. Similar results were observed, even in 484 patients who had both abnormal WT1 and LAIPs values before transplant. A multivariate analysis showed that MRDco+ was an independent risk factor for leukemia relapse after transplant in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The combined use of FCM and WT1 monitoring could distinguish between patients with low and high risks of relapse. Various positive MRD standards were useful for guiding intervention.

语种英语
WOS记录号WOS:000321520500012
项目编号30971292
资助机构National Natural Science Foundation of China ; National High-Tech R&amp ; D Program of China (863 Program) ; Ministry of Health of China ; Beijing Key Laboratory for Hematopoietic Stem Cell Transplantation
引用统计
被引频次:34[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65729
专题北京大学第二临床医学院
北京大学第二临床医学院_血液科
作者单位1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Zhao, Xiao-su,Yan, Chen-hua,Liu, Dai-hong,et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity[J]. ANNALS OF HEMATOLOGY,2013,92(8):1111-1119.
APA Zhao, Xiao-su.,Yan, Chen-hua.,Liu, Dai-hong.,Xu, Lan-ping.,Liu, Yan-rong.,...&Huang, Xiao-jun.(2013).Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.ANNALS OF HEMATOLOGY,92(8),1111-1119.
MLA Zhao, Xiao-su,et al."Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity".ANNALS OF HEMATOLOGY 92.8(2013):1111-1119.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Xiao-su]的文章
[Yan, Chen-hua]的文章
[Liu, Dai-hong]的文章
百度学术
百度学术中相似的文章
[Zhao, Xiao-su]的文章
[Yan, Chen-hua]的文章
[Liu, Dai-hong]的文章
必应学术
必应学术中相似的文章
[Zhao, Xiao-su]的文章
[Yan, Chen-hua]的文章
[Liu, Dai-hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。